PuraPharm Corporation Limited (1498.HK)
HKD 0.5
(-1.0%)
HKD 0.5
(-1.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -26.16 Million HKD | 81.11% |
| 2022 | -46.33 Million HKD | -123.38% |
| 2021 | -40.02 Million HKD | 58.5% |
| 2020 | 114.67 Million HKD | 675.97% |
| 2019 | -122.19 Million HKD | -87.71% |
| 2018 | 85.7 Million HKD | 104.78% |
| 2017 | 21.89 Million HKD | -60.69% |
| 2016 | 64.53 Million HKD | -5.82% |
| 2015 | 59.14 Million HKD | -9.33% |
| 2014 | 65.22 Million HKD | 32.12% |
| 2013 | 49.36 Million HKD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 4.43 Million HKD | 118.09% |
| 2023 Q2 | 2.48 Million HKD | 107.31% |
| 2023 FY | - HKD | 81.11% |
| 2023 Q4 | -5.47 Million HKD | -320.5% |
| 2022 FY | - HKD | -123.38% |
| 2022 Q4 | -33.94 Million HKD | -287.46% |
| 2022 Q2 | 18.1 Million HKD | -13.99% |
| 2021 Q2 | 46.7 Million HKD | 60.43% |
| 2021 FY | - HKD | 58.5% |
| 2021 Q4 | 21.05 Million HKD | -54.92% |
| 2020 Q2 | 13.63 Million HKD | 186.79% |
| 2020 FY | - HKD | 675.97% |
| 2020 Q4 | 29.11 Million HKD | 113.47% |
| 2019 FY | - HKD | -87.71% |
| 2019 Q2 | 754 Thousand HKD | -91.24% |
| 2019 Q4 | 4.75 Million HKD | 530.64% |
| 2018 FY | - HKD | 104.78% |
| 2018 Q4 | 8.61 Million HKD | -76.23% |
| 2018 Q2 | 36.22 Million HKD | 1239.6% |
| 2017 Q2 | 25.07 Million HKD | -33.84% |
| 2017 Q4 | -3.17 Million HKD | -112.68% |
| 2017 FY | - HKD | -60.69% |
| 2016 FY | - HKD | -5.82% |
| 2016 Q2 | 17.79 Million HKD | -66.11% |
| 2016 Q4 | 37.9 Million HKD | 112.97% |
| 2015 Q2 | 6.63 Million HKD | -84.95% |
| 2015 FY | - HKD | -9.33% |
| 2015 Q4 | 52.5 Million HKD | 691.36% |
| 2014 Q4 | 44.08 Million HKD | 108.53% |
| 2014 FY | - HKD | 32.12% |
| 2014 Q2 | 21.14 Million HKD | 22.67% |
| 2013 FY | - HKD | 0.0% |
| 2013 Q4 | 17.23 Million HKD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 150.4 Million HKD | 117.4% |
| Grand Pharmaceutical Group Limited | 2.96 Billion HKD | 100.882% |
| Extrawell Pharmaceutical Holdings Limited | -129.51 Million HKD | 79.795% |
| Wai Yuen Tong Medicine Holdings Limited | 113.79 Million HKD | 122.996% |
| Qianhai Health Holdings Limited | -50.22 Million HKD | 47.901% |
| Lee's Pharmaceutical Holdings Limited | 109.82 Million HKD | 123.829% |
| Essex Bio-Technology Limited | 418.37 Million HKD | 106.255% |
| Tongfang Kontafarma Holdings Limited | 76.63 Million HKD | 134.148% |
| SSY Group Limited | 2.11 Billion HKD | 101.238% |
| JBM (Healthcare) Limited | 204.39 Million HKD | 112.803% |
| Jacobson Pharma Corporation Limited | 429.92 Million HKD | 106.087% |
| China Resources Pharmaceutical Group Limited | 15.43 Billion HKD | 100.17% |